NYSE:BHCPharmaceuticals
Xifaxan Trial Setback Puts Bausch Health Growth Plans Under Review
Bausch Health Companies (NYSE:BHC) reported a significant setback after a phase 3 clinical trial for Xifaxan failed to support a planned label expansion.
The trial aimed to widen approved uses of Xifaxan, a key product in the company’s gastroenterology portfolio.
This outcome affects a planned growth avenue and comes as Bausch Health assesses ways to address future patent expiration risks.
Bausch Health Companies, known for its diversified portfolio in eye health, gastroenterology and...